May 16, 2019 7:30am EDT Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
May 07, 2019 4:01pm EDT Rigel Announces First Quarter 2019 Financial Results and Provides Company Update
Apr 30, 2019 7:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update
Feb 28, 2019 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Feb 21, 2019 7:30am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results
Jan 23, 2019 7:30am EST Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
